Navigation Links
Calando in Medical Technology

Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA

PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Arrowhead Research Corporation (NASDAQ:ARWR) announced today that majority-owned subsidiary Calando Pharmaceuticals has published results in the Proceedings of the National Academy of Sciences (PNAS) of the first non-human primate study to use multi...

Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

PASADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - Arrowhead Research Corporation (NASDAQ: ARWR) announced the publication by its majority-owned subsidiary Calando Pharmaceuticals, Inc. of a study demonstrating the anti-proliferative effect of the siRNA sequence selected as the therapeutic component ...

Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting

Novel Systems May Provide Cancer Patients With Improved Potential to Battle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Arrowhead Research Corporation announced today that two of its majority-owned subsidiaries, Insert Therapeutics Inc. and Calando Pharmaceuticals Inc....

Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal

...s to cause highly targeted gene silencing. About calando Pharmaceuticals Inc. calando Pharmaceuticals Inc. (www.calandopharma.com), a ma...with pharmaceutical and biotechnology companies. calando Technology Calando's cyclodextrin-containing pol...

Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate

...f Cancer Research (AACR). This paper describes how calando researchers and their collaborators determined the...Chief Executive Officer. Petrovich also noted that calando has filed for patent protection on several siRNA d...s to cause highly targeted gene silencing. About calando Pharmaceuticals Inc. ...

Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting

...," said Jeremy Heidel, Chief Scientific Officer at calando Pharmaceuticals. "This formulation was well-tolera... cells has also been accomplished in vivo. About calando Pharmaceuticals Inc. calando Pharmaceuticals Inc. (
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
Other Contents